1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,800 | 22,000 | 12:46 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:32 | DUALITYBIO-B (09606): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 11:26 | Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact | 8 | FierceBiotech | ||
| 06:30 | DualityBio partners with Genentech on cancer drug development | 19 | Investing.com | ||
| 06:22 | DualityBio und Genentech schließen milliardenschweren Pakt zur Entwicklung von Krebsmedikamenten | 20 | Investing.com Deutsch | ||
| 06:08 | Duality Biotherapeutics, Inc.: DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform | 91 | PR Newswire | Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical... ► Artikel lesen | |
| 03:47 | DUALITYBIO-B Reaches Global ADC Partnership With Roche's Genentech; Milestone Payments Exceed USD1 billion | 16 | AASTOCKS | ||
| 01:18 | DUALITYBIO-B (09606): INSIDE INFORMATION - GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT WITH GENENTECH, INC. TO DEVELOP NEXT-GENERATION ... | 1 | HKEx | ||
| 14.08. | UBS Initiates Coverage on DUALITYBIO-B with Buy Rating, TP at HKD320 | 5 | AASTOCKS | ||
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.08. | DUALITYBIO-B (09606): DATE OF BOARD MEETING | 2 | HKEx | ||
| 29.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | 7 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): (1) CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT; (2) WAIVER FROM STRICT COMPLIANCE WITH RULES ... | 6 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): GRANT OF RESTRICTED SHARE UNITS UNDER THE 2025 SHARE SCHEME | 1 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 12.06. | DUALITYBIO-B (09606): ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE | 2 | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE ON COUNSELLING FROM SHANGHAI SECURITIES REGULATORY BUREAU REGARDING PROPOSED LISTING OF RMB ... | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | - | HKEx | ||
| 03.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,85 | +0,21 % | BioNTech-Aktie: Gibt sie jetzt weiter Vollgas? | Die BioNTech-Aktie hat mit einer Kursexplosion von rund +25% auf 116,57 US$ in der vergangenen Woche mächtig für Aufsehen gesorgt. Jetzt stellt sich die Frage: Bleibt sie auf dem Gaspedal? Was ein Wettbewerber... ► Artikel lesen | |
| MODERNA | 125,58 | +2,48 % | Moderna-Aktie: 77 oder 170 US$ - wer hat denn nun Recht? | Die Moderna-Aktie ist dieser Tage nichts für Anleger mit schwachen Nerven. Nach ihrem gewaltigen Kursfeuerwerk am Mittwoch von +177% sackte sie am Donnerstag um -23% ab. Am Freitag übernahmen aber wieder... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,390 | +0,39 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,334 | +2,77 % | Defence Therapeutics Inc.: Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs | Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 44,190 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| CELULARITY | 2,090 | -0,48 % | Celularity Inc.: Celularity Provides Update Regarding Nasdaq Listing Compliance | FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,600 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ERASCA | 19,505 | 0,00 % | Erasca, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 26,090 | 0,00 % | Shandong Wit Dyne Health Co., Ltd. Reports Retreat In H1 Income | ||
| PROPANC BIOPHARMA | 2,250 | +0,90 % | Propanc Biopharma, Inc.: Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit | MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,94 | -0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,440 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,340 | +0,07 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| COGENT BIOSCIENCES | 37,080 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 14,320 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer | Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide... ► Artikel lesen |
Das Unternehmen DUALITY BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,83 % bei einem Aktienkurs von 21,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.